Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The company highlighted that more than 150 cumulative telesurgeries have been successfully performed with SSi Mantra, primarily in India, underscoring growing real‑world use of its platform.
The update describes recent benchmarks, including 18 inter-hospital telesurgeries completed between two Indian cities in eight hours on February 14, 2026, and an earlier 12-hour telesurgery marathon with 24 procedures on December 23, 2025. SS Innovations also announced it will host the Global Multi-Specialty Robotic Surgery Conference 2026 in New Delhi from April 9-11, 2026, where over 20 live telesurgeries using SSi Mantra are planned.
SS Innovations International, Inc. director and 10% owner Frederic H. Moll bought 501,253 shares of common stock in an open-market purchase at $3.99 per share. After this transaction, he directly owned 10,775,485 common shares.
SS Innovations International director Timothy P. Adams increased his indirect stake by buying 300,000 common shares in an open-market transaction at $3.99 per share. The shares are held through the Adams Marriage Trust, which now owns 5,331,902 SSII shares for his benefit.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava, through Sushruta Pvt. Ltd., made an open-market purchase of the company’s common stock. On March 6, 2026, Sushruta Pvt. Ltd. bought 498,753 shares at $4.01 per share, bringing its indirect holding to 109,851,767 shares.
SS Innovations International reported rapid growth for 2025, with revenue rising to $42.5M from $20.6M, driven mainly by higher SSi Mantra system, instrument, and warranty sales. Fourth quarter 2025 revenue reached $14.5M, up sharply from $8.1M, as installations and surgeries increased.
The company reduced its annual net loss to $12.1M from $19.2M, though operating cash flow was negative at $18.5M. Total assets grew to $74.2M and stockholders’ equity to $38.2M, supported by significant financing, including a post‑quarter private placement raising about $18.6M in gross proceeds.
Management highlighted strong adoption of the SSi Mantra in India, expansion into new geographies, and ongoing work toward U.S. FDA 510(k) review targeted for mid‑2026 and European Union CE marking. They anticipate continued strong growth in 2026 as more systems are deployed and robotic procedures scale.
SS Innovations International, Inc. files its annual report describing rapid expansion in surgical robotics focused on making robotic surgery more affordable, especially in India and other underserved markets. The company’s SSi Mantra system has received Indian CDSCO approval, ISO 13485 certification, and additional clearances in multiple countries.
As of December 31, 2025, SSi Mantra had 168 installed systems across 10 countries and was used in 7,885 procedures, most in general surgery and urology, with more than 120 telesurgeries completed over distances up to thousands of miles. On March 6, 2026, the company completed a private placement of 5,774,839 common shares for gross proceeds of $18,621,498 to fund working capital, global growth initiatives, and preparation for U.S. and EU market entry.
SS Innovations International, Inc. completed a private placement of common stock on March 6, 2026, raising approximately $18.6 million in gross proceeds from the sale of 5,774,839 shares.
The company plans to use the net proceeds for working capital and general corporate purposes, including growth initiatives in India and other existing global markets and preparation for entry into the United States and European Union markets. A $2.5 million non-affiliate investment will trigger a $175,000 cash commission and five-year warrants for 41,667 shares at $3.45 per share to a FINRA member firm. The company expects FDA review of its 510(k) for the SSi Mantra system to be completed by mid-2026 and is pursuing European Union CE marking, which it believes it can obtain in 2026.
SS Innovations International, Inc. executive Barry F. Cohen, COO – Americas, reported an insider transaction involving company common stock. He tendered 32,000 shares of common stock at $6.63 per share to a non-affiliated third-party lender in satisfaction of principal and interest on a $200,000 promissory note. Following this stock-for-debt repayment, he continues to hold 7,806,088 common shares directly.
SS Innovations International, Inc. director and Asia Pacific CEO Vishwajyoti Pascual Srivastava reported a bona fide gift transfer of 2,000,000 shares of common stock. The shares were transferred at a price of $0.00 per share and are held indirectly through Matilda Pvt. Ltd., an entity in which he has a controlling interest. Following the transaction, 2,000,000 shares are reported as indirectly owned through Matilda Pvt. Ltd.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 2,000,000 shares of common stock. The transfer was made at a reported price of $0.00 per share and is classified as an indirect transaction through Sushruta Pvt. Ltd., which holds the shares of record. Following this gift transfer, indirect holdings reported for this entity total 109,353,014 shares of common stock.